Progyny (NASDAQ:PGNY) Releases FY 2024 Earnings Guidance

Progyny (NASDAQ:PGNY) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 1.540-1.570 for the period, compared to the consensus estimate of 0.710. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Progyny also updated its Q4 guidance to $0.07-0.10 EPS.

Analyst Ratings Changes

Several brokerages recently issued reports on PGNY. JPMorgan Chase & Co. reduced their price target on shares of Progyny from $31.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, September 19th. Leerink Partners cut their target price on shares of Progyny from $25.00 to $21.00 and set a “market perform” rating on the stock in a research report on Thursday, September 19th. Truist Financial cut their target price on shares of Progyny from $33.00 to $26.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of Progyny in a research report on Tuesday, October 1st. Finally, Leerink Partnrs downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Progyny presently has an average rating of “Hold” and a consensus price target of $27.73.

Progyny Stock Performance

NASDAQ PGNY traded up $0.12 during trading hours on Tuesday, reaching $17.18. 1,996,870 shares of the company’s stock were exchanged, compared to its average volume of 1,371,571. The company’s 50-day moving average is $18.01 and its two-hundred day moving average is $23.73. Progyny has a one year low of $13.93 and a one year high of $42.08. The company has a market capitalization of $1.55 billion, a price-to-earnings ratio of 27.27, a price-to-earnings-growth ratio of 1.57 and a beta of 1.44.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.